Success Stories: Advancing U.S. Cardiology—How a Research-Driven Physician from Bangladesh Secured NIW Approval
Client’s Testimonial:
“Victoria Chen and her team have managed to make a complicated, drawn-out and difficult process such as the EB2-NIW application seem easy, smooth and straightforward, and I can think of no higher praise than that. I am grateful to have had a chance to work with you. You have lived up to every bit of your stellar reputation. I am very grateful for your guidance and wisdom throughout this process.”
On June 12th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a physician-scientist in the field of cardiology (Approval Notice).
General Field: Cardiology
Position at the Time of Case Filing: Interventional Cardiology Fellow
Country of Origin: Bangladesh
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: June 12th, 2025
Processing Time: 1 month, 19 days (Premium Processing Requested)
Case Summary:
We are pleased to announce the approval of an NIW petition filed on behalf of a Bangladeshi physician and researcher specializing in cardiology. This client’s proposed endeavor to develop medications, tools, and techniques to mitigate the onset and progression of atherosclerosis and heart failure was recognized for its substantial merit and national importance. His research spans both innovative clinical applications and collaborative industry efforts, all focused on enhancing cardiovascular health outcomes in the United States.
Innovative Cardiovascular Research Driving National Health
The client’s research addresses some of the most pressing challenges in cardiovascular care, including catheter-device-related infections, diuretic resistance, and catastrophic antiphospholipid syndrome. Through original studies and clinical insight, his work contributes to more effective diagnostics, therapeutic tools, and treatment strategies aimed at reducing the burden of cardiovascular disease.
Scholarly Productivity and Impact
With 16 peer-reviewed journal articles and 22 conference abstracts, the client has consistently produced impactful research. His work has been cited over 330 times, and at least six of his papers rank among the top 10–20% most cited in clinical medicine for their publication years. These metrics reflect both scholarly recognition and real-world influence.
In addition to his publication record, the client has also served as a peer reviewer for several academic journals, further demonstrating his standing within the research community.
Strategic Case Framing
To establish eligibility for the National Interest Waiver, our legal team emphasized the national importance of the client’s work and his strong positioning to advance his research objectives. We supported the petition with letters from respected experts and documented how his innovations aligned with U.S. public health and economic interests, particularly in combating heart failure and atherosclerosis, which remain among the leading causes of mortality and healthcare expenditure in the United States.
His case was further supported by the signed recommendation letters from his fellow peers, one of which is mentioned below:
“Given that cardiovascular disease remains the leading cause of mortality in the U.S., [client’s] improvements to both treatment efficacy and procedural safety are essential for addressing critical public health priorities.”
Continued Impact on U.S. HealthcareNow approved under EB-2 NIW, our client is set to continue his work in cardiovascular research and patient care. His commitment to advancing clinical outcomes through innovation and interdisciplinary collaboration positions him to make enduring contributions to the American healthcare system. NAILG is proud to have played a role in this important success.